top of page
Latest News
Real-World Study Led by Observational and Pragmatic Research Institute Suggests GLP-1 Receptor Agonists May Reduce COPD Exacerbation Risk in Patients with Type 2 Diabetes
An international real-world study coordinated by the Observational and Pragmatic Research Institute (OPRI) suggests that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may be associated with fewer exacerbations and reduced corticosteroid use in patients living with chronic obstructive pulmonary disease (COPD) and type 2 diabetes (T2D). The findings, published in Pragmatic and Observational Research , are based on data from a large UK primary care population. COPD and
Mar 232 min read
A recent study shows a surprising improvement in respiratory outcomes when patients with asthma receive weight loss drugs.
Singapore, [10 April 2025] – A large real world evidence study conducted by leading respiratory experts found patients with asthma who...
Apr 8, 20252 min read
bottom of page